Claims
- 1. Prostaglandins E represented by a general formula:
- in which X represents: ##STR47## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 represents: a hydrogen atom;
- R.sub.5 represents: a hydrogen atom;
- R.sub.6 represents: a C.sub.5 -C.sub.9 alkyl group which may have a branch or a double bond,
- in which the C.sub.2 -C.sub.3 bond is a single bond.
- 2. Prostaglandin E as described in claim 1, wherein X is ##STR48##
- 3. Prostaglandin E as described in claim 1, wherein X is ##STR49##
- 4. Prostaglandin E as described in claim 1, wherein R.sub.6 is C.sub.6 -C.sub.9 alkyl group.
- 5. Prostaglandin E as described in claim 1, wherein the general formula is ##STR50##
- 6. Prostaglandin E as described in claim 5, being 13,14-dihydro-6,15-diketo-19-methyl-PGE.sub.1 or alkyl ester thereof.
- 7. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E represented by a general formula: ##STR51## in which X represents: ##STR52## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 represents: a hydrogen atom;
- R.sub.5 represents: a hydrogen atom;
- R.sub.6 represents: a C.sub.5 -C.sub.9 alkyl group which may have a branch or a double bond,
- in which the C.sub.2 -C.sub.3 bond is a single bond.
- 8. An anti-ulcer composition as described in claim 7, wherein X is ##STR53##
- 9. An anti-ulcer composition as described in claim 7, wherein X is ##STR54##
- 10. An anti-ulcer composition as described in claim 7, wherein R.sub.6 is C.sub.6 -C.sub.9 alkyl group.
- 11. An anti-ulcer composition as described in claim 7, wherein the general formula is ##STR55##
- 12. An anti-ulcer composition as described in claim 11, being 13,14-dihydro-6,15-diketo-19-methyl-PGE.sub.1 or alkyl ester thereof.
Priority Claims (2)
Number |
Date |
Country |
Kind |
62-18820 |
Jan 1987 |
JPX |
|
62-65352 |
Mar 1987 |
JPX |
|
Parent Case Info
This is a continuation of application Ser. No. 07/681,031 filed Apr. 5, 1991, now U.S. Pat. No. 5,225,439 which is a continuation of application Ser. No. 07/406,830 filed Sep. 12, 1989, abandoned, which is a continuation-in-part of application Ser. No. 07/149,445 filed Jan. 28, 1988, abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3836378 |
Samuelsson |
Sep 1974 |
|
Non-Patent Literature Citations (2)
Entry |
Anggard Acta Physiol Scand 66 509 (1966). |
Jones Proceedings of the BPS 17-19 Dec. 1975 p. 340p. |
Continuations (2)
|
Number |
Date |
Country |
Parent |
681031 |
Apr 1991 |
|
Parent |
406830 |
Sep 1989 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
149445 |
Jan 1988 |
|